Capula Management Ltd Takes Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Capula Management Ltd acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 4th quarter, Holdings Channel.com reports. The firm acquired 14,647 shares of the company’s stock, valued at approximately $354,000.

A number of other hedge funds have also recently added to or reduced their stakes in HIMS. SlateStone Wealth LLC raised its holdings in shares of Hims & Hers Health by 4.0% during the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after purchasing an additional 413 shares during the period. Blume Capital Management Inc. grew its position in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 600 shares during the last quarter. Harbour Investments Inc. raised its stake in Hims & Hers Health by 18.8% during the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock worth $127,000 after acquiring an additional 833 shares during the period. Stonekeep Investments LLC lifted its holdings in Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after acquiring an additional 882 shares during the last quarter. Finally, LPL Financial LLC lifted its holdings in Hims & Hers Health by 1.0% in the fourth quarter. LPL Financial LLC now owns 97,958 shares of the company’s stock worth $2,369,000 after acquiring an additional 980 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. BTIG Research assumed coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Piper Sandler increased their target price on Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 25th. Truist Financial boosted their price target on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a report on Wednesday, February 26th. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Finally, Leerink Partners lifted their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $37.31.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $27.71 on Tuesday. The business’s fifty day moving average is $39.76 and its 200-day moving average is $30.11. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98. The stock has a market cap of $6.16 billion, a PE ratio of 62.97 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Michael Chi sold 7,259 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $24.07, for a total value of $174,724.13. Following the transaction, the insider now owns 193,601 shares in the company, valued at $4,659,976.07. This represents a 3.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 4,152 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the sale, the insider now owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 809,806 shares of company stock valued at $30,923,658. Company insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.